

N⁶-modified cAMP derivatives that activate protein kinase A also act as full agonists of murine HCN2 channels

Received for publication, July 17, 2019, and in revised form, October 15, 2019. Published, Papers in Press, October 15, 2019, DOI 10.1074/jbc.RA119.010246

Tim Leybold^{†1}, Michele Bonus^{§1}, Felix Spiegelhalter[‡], Frank Schwede[¶], Tina Schwabe[‡],  Holger Gohlke^{§||}, and  Jana Kusch^{‡2}

From the [‡]Friedrich Schiller University, University Hospital Jena, Institute of Physiology II, Kollegiengasse 9, 07743 Jena, Germany, the [§]Institute for Pharmaceutical and Medical Chemistry, Heinrich Heine University, Universitätsstraße 1, 40225 Düsseldorf, Germany, [¶]BIOLOG LSI GmbH & Co. KG, 28199 Bremen, Germany, and the ^{||}John von Neumann Institute for Computing, Jülich Supercomputing Centre and Institute for Complex Systems - Structural Biochemistry (ICS 6), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany

Edited by Mike Shipston

cAMP acts as a second messenger in many cellular processes. Three protein types mainly mediate cAMP-induced effects: PKA, exchange protein directly activated by cAMP (Epac), and cyclic nucleotide–modulated channels (cyclic nucleotide–gated or hyperpolarization-activated and cyclic nucleotide–modulated (HCN) channels). Discrimination among these cAMP signaling pathways requires specific targeting of only one protein. Previously, cAMP modifications at position N⁶ of the adenine ring (PKA) and position 2′-OH of the ribose (Epac) have been used to produce target-selective compounds. However, cyclic nucleotide–modulated ion channels were usually outside of the scope of these previous studies. These channels are widely distributed, so possible channel cross-activation by PKA- or Epac-selective agonists warrants serious consideration. Here we demonstrate the agonistic effects of three PKA-selective cAMP derivatives, N⁶-phenyladenosine-3′,5′-cyclic monophosphate (N⁶-Phe-cAMP), N⁶-benzyladenosine-3′,5′-cyclic monophosphate (N⁶-Bn-cAMP), and N⁶-benzoyl-adenosine-3′,5′-cyclic monophosphate (N⁶-Bnz-cAMP), on murine HCN2 pacemaker channels. Electrophysiological characterization in *Xenopus* oocytes revealed that these derivatives differ in apparent affinities depending on the modification type but that their efficacy and effects on HCN2 activation kinetics are similar to those of cAMP. Docking experiments suggested a pivotal role of Arg-635 at the entrance of the binding pocket in HCN2, either causing stabilizing cation– π interactions with the aromatic ring in N⁶-Phe-cAMP or N⁶-Bn-cAMP or a steric clash with the aromatic ring in N⁶-Bnz-cAMP. A reduced apparent affinity of N⁶-Phe-cAMP toward the variants R635A and R635E strengthened that notion. We conclude that some PKA activators also effectively activate HCN2 channels. Hence, when studying PKA-mediated cAMP signaling with cAMP derivatives in a native environment, activation of HCN channels should be considered.

cAMP, the first identified second messenger (1), plays a key role in living organisms ranging from *Dictyostelium* to *Homo sapiens*. It is involved in a wide variety of cellular processes, including proliferation, differentiation, secretion, migration, pacemaking, sensation, and apoptosis. The concentration of cytosolic cAMP is controlled by the action of adenylyl cyclases, catalyzing the conversion of ATP to cAMP, and cyclic nucleotide phosphodiesterases, catalyzing the conversion of cAMP to 5′-AMP. In mammalian cells, four main types of proteins respond to cAMP: PKA, exchange protein directly activated by cAMP (Epac1 and Epac2),³ CN-modulated ion channels (cyclic nucleotide–gated channels and hyperpolarization-activated and cyclic-nucleotide modulated (HCN) channels) (2) and the relatively new class of Popeye domain–containing proteins (3).

HCN channels, as one type of CN-modulated ion channels, are activated by hyperpolarizing membrane potentials as a primary stimulus but are secondarily stimulated by direct binding of cyclic nucleotides, mainly cAMP, to intracellular binding sites (4–10). Structurally, HCN channels belong to the superfamily of tetrameric voltage-gated ion channels (11). In these channels, each subunit contains a voltage sensor domain and a pore domain. In contrast to most other members of this superfamily, HCN channel subunits additionally contain a cyclic nucleotide–binding domain (CNBD) in the C terminus, which is connected to the membrane portion by a so-called C-linker (12). It has been shown that the unoccupied CNBD together with the C-linker has an inhibitory effect on channel gating, which is relieved by CN binding (13). Such a relieving effect is reflected by a shift of the steady-state activation curve to more depolarized voltages, thereby increasing the maximum current amplitude, accelerating activation and decelerating deactivation (14, 15).

The CNBD is a highly conserved structure (16). Combined data from PKA, Epac, and ion channel studies illustrate that CNBDs use a common mechanism to bind and sense cAMP

This work was supported by grant DFG Research Unit 2518 Dynlon of the Deutsche Forschungsgemeinschaft (projects P2 (KU 3092/2–1) and P7 (GO 1367/2–1)). F. S. is Head of Research and Development of the BIOLOG Life Science Institute, which sells the cAMP analogs that were used in this study.

[†]These authors contributed equally to this work.

²To whom correspondence should be addressed. E-mail: jana.kusch@med.uni-jena.de.

³The abbreviations used are: Epac, exchange protein directly activated by cAMP; CN, cyclic nucleotide; HCN, hyperpolarization-activated and cyclic nucleotide–modulated; CNBD, cyclic nucleotide–binding domain; N⁶-Phe-cAMP, N⁶-phenyladenosine-3′,5′-cyclic monophosphate; N⁶-Bn-cAMP, N⁶-benzyladenosine-3′,5′-cyclic monophosphate; N⁶-Bnz-cAMP, N⁶-benzoyl-adenosine-3′,5′-cyclic monophosphate; RMSD, root mean square deviation.

(17). This similarity in the cAMP-binding mechanism of all cAMP-responsive proteins makes it challenging to target only one type of protein to discriminate between the different cAMP signaling pathways. However, discrimination between two proteins, PKA and Epac, could be realized and has been used widely (e.g. (18–22)). Although Epac tolerates 2'-OH modifications, modifications at the N⁶ position of the purine ring are not accepted by this protein. However, such N⁶-modified derivatives are often potent agonists for PKA and can be used to exclude Epac activation (23). Notably, fully functional ion channels were often outside the scope when studying the selectivity of cAMP derivatives.

Besides a systematic study performed by Ng et al. (24) comparing binding and gating parameters for different cyclic nucleotides in whole HCN channels, the effect of purine ring modifications at cAMP on functional channels have so far not been tested systematically. To contribute to the urgent problem of developing cAMP analogs that can discriminate between the different cAMP-binding proteins, here we tested three N⁶-modified cAMP derivatives: N⁶-phenyladenosine-3',5'-cyclic monophosphate (N⁶-Phe-cAMP), N⁶-benzyladenosine-3',5'-cyclic monophosphate (N⁶-Bn-cAMP), and N⁶-benzoyladenosine-3',5'-cyclic monophosphate (N⁶-Bnz-cAMP), known to be activators of PKA, on functional HCN2 channels. We show that all of them are HCN2 channel activators with efficacies similar to cAMP but with different apparent affinities. Docking and mutagenesis experiments revealed the specific interactions between molecule and binding pocket that underlie those differences.

Results

Effect of the native ligand cAMP on HCN2 channels in oocyte macropatches

HCN2 channels produce slowly activating inward currents in response to hyperpolarizing voltage jumps. It has been shown that the cyclic nucleotide-binding domain has an inhibitory effect on channel gating that is relieved by cAMP binding (13). Such a relieving effect is reflected by an increase in current amplitude at a given voltage, by a shift of the voltage of half-maximum activation, $V_{1/2}$, to more depolarized values, and by an acceleration of activation kinetics and a deceleration of deactivation kinetics (14). This could also be observed here for mHCN2 channels expressed in *Xenopus laevis* oocytes (Fig. 1).

Fig. 1, A and B, shows representative current traces and the respective protocols used to determine channel activation at varying agonist concentrations at a given command voltage of −130 mV (Fig. 1A) and to determine channel activation at varying voltages at zero or saturating agonist concentrations (Fig. 1B), respectively. The cAMP concentration required to cause EC₅₀, a measure of the apparent affinity of the agonist to the receptor, was determined by approximating the Hill equation (Equation 1) to relative current amplitudes plotted against the cAMP concentration (Fig. 1C). Current amplitudes were obtained from tail currents at −100 mV following an activating pulse of −130 mV. The EC₅₀ value was found to be 21.3 ± 3.3 nM, and the Hill coefficient was 1.1 ± 0.2. From this, 10 μM was defined as the saturating concentration for all experiments.




Figure 1. cAMP effects on steady-state and nonsteady state parameters of mHCN2 channel activation. A, protocol and representative current traces to study concentration-dependent gating at a fixed command voltage. Tail currents were obtained from a −100 mV pulse following an activating −130 mV pulse. B, protocol and representative current traces (exemplary of a saturating concentration of 10 μM cAMP) to study voltage-dependent gating at a fixed agonist concentration. A voltage family from −70 mV to −150 mV was applied with 10-mV increments. Tail currents were obtained from a −100 mV pulse following the variable test pulse. C, concentration–response relationship for cAMP. Mean values for I/I_{max} were obtained from six to 13 recordings and plotted against the cAMP concentration. The Hill equation (Equation 1) was approximated to the data, yielding EC_{50} (21.3 ± 3.3 nM) and H (1.1 ± 0.2), respectively. D, steady-state activation relationship at zero and saturating [cAMP]. Mean values for relative current amplitudes (I/I_{max}) for zero cAMP ($n = 14$) and for saturating cAMP of 10 μM ($n = 13$) were plotted against the command voltage. The Boltzmann equation was approximated to the data, yielding $V_{1/2} = -117.8 \pm 1.5$ mV and a slope of $z\delta = 4.2 \pm 0.3$ for zero and $V_{1/2} = -97.9 \pm 1.9$ mV and a slope of $z\delta = 4.2 \pm 0.3$ for 10 μM cAMP. E, activation kinetics at different cAMP concentrations. Activation time constants were obtained from approximating a monoexponential function (Equation 3) to the current time courses, yielding $\tau_{a,conc}$. Mean values were obtained from three to seven recordings. The protocol used is shown in A. F, activation kinetics at different command voltages at zero and saturating [cAMP]. Activation time constants were obtained from approximating a monoexponential function (Equation 3) to the current time courses, yielding $\tau_{a,voltage}$. Mean values were obtained from 14 recordings for zero and 13 recordings for 10 μM cAMP. The protocol used is shown in B.

To estimate $V_{1/2}$, relative current amplitudes were plotted versus the command voltage. The Boltzmann equation was fitted to the data points of individual recordings, yielding $V_{1/2}$ under control conditions of -117.8 ± 1.5 mV and after application of 10 μM cAMP of -97.9 ± 1.9 mV. Thus, the steady-state activation was shifted by 19.9 ± 1.2 mV to more depolarized values because of cAMP binding (Fig. 1D). The slopes of

HCN2 channel activation by N^6 -modified cAMP derivatives




Figure 2. Structure and apparent affinities of the three tested derivatives. A, molecular formulas for three N^6 -modified derivatives known to activate PKA. B, representative current responses before and after application of the respective ligand. Black traces represent recordings in the absence of the ligand, and colored traces represent recordings during application of a saturating concentration of the respective ligand. Each ligand turned out to be an activator of heterologously expressed HCN2 channels. C, concentration–response relationships for the three derivatives (colored symbols and fits) compared with mHCN2 WT data (black symbols and fits). The Hill equation (Equation 1) was approximated to the data to obtain EC_{50} and H . Error bars indicate S.E. D, box plot of EC_{50} values obtained from C. Filled circles indicate individual recordings. Error bars indicate S.D. E, box plot of Hill coefficients obtained from C. Filled circles indicate individual recordings. Error bars indicate S.D.

the curves were similar with and without cAMP (4.2 ± 0.2 and 4.2 ± 0.3 mV/e-fold change, respectively).

The time constant of activation, given as $\tau_{a,conc}$, decreased with increasing cAMP concentrations (Fig. 1E). Furthermore, the time constant of activation decreased with increasing hyperpolarizing voltages under control conditions without cAMP as well as after application of $10 \mu\text{M}$ cAMP (Fig. 1F).

All three tested cAMP derivatives were able to promote HCN2 channel activation

We tested three cAMP derivatives, used as PKA activators, for their ability to activate HCN2 channels: N^6 -Phe-cAMP, N^6 -Bn-cAMP, and N^6 -Bnz-cAMP (Fig. 2A). In these derivatives, a phenyl group, a benzyl group, or a benzoyl group, respectively, is attached to the amino group in position 6 of the adenine moiety. All three N^6 -modified derivatives have been shown to be site-selective for site A of both PKA type I and II (27–29).

To test whether the three cAMP derivatives are able to modulate HCN2 channels, channel activation was monitored at

zero cAMP and in the presence of different agonist concentrations. Representative current recordings for zero cAMP and saturation are shown in Fig. 2B. All three derivatives caused an increase in current amplitude and acceleration of the activation kinetics, as known for cAMP (Fig. 1).

cAMP modifications at position N^6 affected the apparent affinity of the agonist for HCN2

To study the concentration dependence in more detail, concentration–response relationships were recorded for each derivative (Fig. 2C) and compared with the relationship for cAMP. For all cases, the Hill equation (Equation 1) was approximated to the relative currents of each individual recording. The results for EC_{50} and the Hill coefficient, H , are summarized in Fig. 2, D and E, respectively. The nature of the N^6 modification had a major influence on the apparent affinity ($EC_{50,\text{Phe}} = 3.02 \pm 0.83$ nM, $EC_{50,\text{Bn}} = 5.12 \pm 1.03$ nM, $EC_{50,\text{Bnz}} = 374 \pm 91.3$ nM) (Fig. 2D). Adding a phenyl or benzyl group to position N^6 shifted the EC_{50} value to lower concentrations compared with native cAMP, causing an apparent affinity one order of magnitude higher than for




Figure 3. Efficacy of the three tested derivatives. A, steady-state activation relationships at zero and saturating agonist concentrations. The graphs show the relationships of the tested derivatives at saturating concentrations and in the absence of any ligand. Except for *N*⁶-Bnz-cAMP, for which 100 μ M was used as a saturating concentration, the concentration was 10 μ M for saturation. $I/I_{\max}$ are mean values obtained from three to six recordings. The Boltzmann equation was approximated to the relative current values to yield $V_{1/2}$. The results of the fits were as follows: -97.5 ± 2.0 mV for *N*⁶-Phe-cAMP, -104.9 ± 2.7 mV for *N*⁶-Bn-cAMP, and -98.3 ± 1.4 mV for *N*⁶-Bnz-cAMP. The slopes were 3.4 ± 0.2 , 4.1 ± 0.2 , and 4.4 ± 0.3 , respectively. B and C, comparison of the efficiency of the three derivatives compared with cAMP in two measures. B, box plots of $I_{\max}/I_{\max,cAMP}$. Filled circles indicate individual recordings. Error bars indicate S.D. C, box plots of $\Delta V_{1/2}$. Filled circles indicate individual recordings. Error bars indicate S.D.

cAMP. However, adding a benzoyl group shifted the EC_{50} value to higher concentrations, indicating an apparent affinity one order of magnitude lower than for cAMP (Fig. 2D). The Hill coefficients for the derivatives were not significantly different from that for cAMP: $H_{\text{Phe}} = 1.4 \pm 0.3$, $H_{\text{Bn}} = 1.2 \pm 0.3$, and $H_{\text{Bnz}} = 0.9 \pm 0.2$ (Student's *t* test, $p = 0.05$) (Fig. 2E).

None of the cAMP modifications tested changed the efficacy

We used two measures to compare the efficacy of the cAMP derivatives with that of native cAMP: the maximal agonist-induced voltage shift ($\Delta V_{1/2,\max}$) and the maximal fractional increase in tail current amplitude ($I_{\max,\text{agonist}}/I_{\max,cAMP}$) observed with saturating agonist concentrations (Fig. 3) (30).

To yield $\Delta V_{1/2,\max}$, $V_{1/2}$ values before and after application of saturating agonist concentrations were estimated by fitting the Boltzmann equation to steady-state activation relationships (Fig. 3A). There was no difference between $\Delta V_{1/2,\max}$ of cAMP and either one of the tested derivatives (16.1 ± 2.3 mV for cAMP, 18.3 ± 1.4 mV for *N*⁶-Phe-cAMP, 18.6 ± 2.4 mV for *N*⁶-Bn-cAMP, and 22.3 ± 1.1 mV for *N*⁶-Bnz-cAMP) (Fig. 3B).

To yield the maximal fractional increase in tail current amplitude, we determined the tail current amplitudes at a test pulse of -100 mV, following a hyperpolarizing pulse of -130 mV, for each cAMP derivative at saturating concentrations and related that to the maximum tail current amplitude of 10 μ M cAMP in the same patch. All derivatives caused a fractional current of around 1.0, suggesting that they all cause a similar current increase as cAMP (Fig. 3C). The values were 1.02 ± 0.14 for *N*⁶-Phe-cAMP, 0.98 ± 0.05 for *N*⁶-Bn-cAMP, and 1.00 ± 0.02 for *N*⁶-Bnz-cAMP (Fig. 3B). Thus, both measures led us conclude that the modifications performed in the tested cAMP derivatives did not affect the efficacy of the agonists.

None of the cAMP modifications tested changed activation kinetics

Fig. 4 summarizes the results regarding activation kinetics upon hyperpolarizing voltage jumps. First, we studied the concentration dependence of these kinetics. For this purpose, we applied the agonists at different concentrations, covering a wide range, and recorded the currents at a nearly saturating




Figure 4. Activation kinetics for the tested cAMP derivatives. A, activation kinetics in dependence on agonist concentration at a given command voltage of -130 mV. $\tau_{a,\text{conc}}$ values, obtained from approximating a monoexponential equation (Equation 3) to the current time courses, are plotted against the cAMP concentration. Mean values were obtained from three to nine recordings. Black symbols in each plot illustrate the case for cAMP. The protocol used is shown in Fig. 1A. B, activation kinetics in dependence on command voltage at a saturating agonist concentration. $\tau_{a,\text{voltage}}$ values were plotted against the command voltage. Open symbols represent recordings in the absence of ligands and filled symbols in the presence of saturating agonist concentrations. Mean values were obtained from three to 19 recordings. The protocol used is shown in Fig. 1B.

voltage of -130 mV. Kinetics were quantified by $\tau_{a,\text{conc}}$ obtained from approximating a monoexponential equation (Equation 3) to the current time courses. The values were plotted against the normalized concentration, which is the ratio of applied concentration and apparent affinity $[\text{agonist}]/EC_{50}$ (Fig. 4A). Such normalization was required because large differences in the EC_{50} values for the derivatives and cAMP did not allow comparison at absolute concentrations. As a result, the concentration dependence of $\tau_{a,\text{conc}}$ for derivatives could be superimposed with that of cAMP.

Second, we studied the voltage dependence of activation kinetics. For this purpose, we applied a family of hyperpolarizing voltages at saturating agonist concentrations and in the absence of agonists, respectively. The results are shown in Fig. 4B. Analogous to the concentration dependence, the voltage dependence of $\tau_{a,\text{voltage}}$ could be superimposed with that of




Figure 5. Predicted binding modes of the tested cAMP derivatives. A–D, predicted binding modes of cAMP (A, gray; crystallographic pose (PDB code 1Q5O (25) shown in gold), N^6 -Phe-cAMP (B, blue), N^6 -Bn-cAMP (C, orange), and N^6 -Bnz-cAMP (D, magenta). In A–C, hydrogen bonds to and from protein side chains are depicted as dashed yellow lines, hydrogen bonds to and from the protein main chain as dashed green lines, and cation- π interactions as dashed blue lines. E, predicted binding mode of the cAMP fragment in N^6 -Bn-cAMP extended with a benzoyl group as found in N^6 -Bnz-cAMP. The steric clash with Arg-635 resulting from this extension is highlighted (red box), explaining the inverted binding mode of N^6 -Bnz-cAMP shown in D.

cAMP. From these results, we conclude that all derivatives had a similar accelerating effect as the native ligand.

Molecular docking suggests a pivotal role of Arg-635 for determining the binding behavior of N^6 -modified derivatives

To determine the structural basis of the higher apparent affinities of N^6 -Phe-cAMP and N^6 -Bn-cAMP and the lower apparent affinity of N^6 -Bnz-cAMP, we predicted and compared the binding modes of cAMP, N^6 -Phe-cAMP, N^6 -Bn-cAMP, and N^6 -Bnz-cAMP in mHCN2] by molecular docking (Fig. 5). The selected docking protocol was able to reproduce the crystallographically determined binding mode of cAMP with a heavy-atom RMSD of 0.60 Å (Fig. 5A), indicating that the binding modes of the N^6 -substituted derivatives can be reliably predicted. The predicted binding modes of the cAMP moiety of

N^6 -Phe-cAMP and N^6 -Bn-cAMP deviate only marginally from the native binding mode of cAMP (heavy-atom RMSDs of 0.73 Å and 0.91 Å, respectively; Fig. 5, B and C). Docking scores (XP GScores) for all three compounds were in a similar range (cAMP, $-13.53 \text{ kcal mol}^{-1}$; N^6 -Phe-cAMP, $-10.20 \text{ kcal mol}^{-1}$; N^6 -Bn-cAMP, $-11.54 \text{ kcal mol}^{-1}$).

Compared with cAMP, the predicted binding modes of N^6 -Phe-cAMP and N^6 -Bn-cAMP reveal stabilizing cation- π and/or π - π stacking interactions between the additional phenyl ring and the side chain of Arg-635 (Fig. 5, A–C), which can explain the higher apparent affinities of these two derivatives. This interaction may be more stable in the case of N^6 -Phe-cAMP because of the more restricted conformational freedom of the N^6 -ring bonds compared with the less restricted N^6 -benzyl carbon bond in N^6 -Bn-cAMP, which

can explain the higher apparent affinity of *N*⁶-Phe-cAMP compared with *N*⁶-Bn-cAMP.

In contrast to the *N*⁶-Phe and *N*⁶-Bn derivatives, the orientation of the cAMP moiety in the predicted binding mode of *N*⁶-Bnz-cAMP did not match the crystallographic pose (RMSD of 8.66 Å) but was instead inverted (Fig. 5D) and associated with a markedly lower docking score ($-6.11 \text{ kcal mol}^{-1}$). To determine why *N*⁶-Bnz-cAMP cannot adopt the binding mode favorable for cAMP and the other *N*⁶-substituted derivatives, we used the predicted binding mode of *N*⁶-Bn-cAMP as a template and replaced the benzyl moiety with a benzoyl moiety. Because of the planarity of the amide group in *N*⁶-Bnz-cAMP, the phenyl ring is then forced into an orientation in which it inevitably clashes with Arg-635 (Fig. 5E), resulting in a strongly unfavorable interaction.

Substituting Arg-635 at the entrance of the binding pocket prevented the higher apparent affinity of *N*⁶-Phe-cAMP

The arginine at position 635 was substituted with either alanine for neutralization (R635A) or glutamate for charge reversal (R635E). If Arg-635 is indeed involved in the higher apparent affinity of *N*⁶-Phe-cAMP and *N*⁶-Bn-cAMP, then the mutations should cause an apparent affinity that resembles that of cAMP to WT channels. To test this, the concentration-activation relationship was tested for *N*⁶-Phe-cAMP in both R635A and R635E. Both constructs, R635A and R635E, formed functional channels and expressed in high densities in *Xenopus* oocytes. First, we tested whether those constructs are still reactive to $10 \mu\text{M}$ cAMP. As for WT channels, we found a substantial current increase and an acceleration of the activation speed (Fig. 6A). When studying the concentration-response relationships for *N*⁶-Phe-cAMP, we found, as expected, that the EC_{50} values for both constructs were increased (Fig. 6, B and C), $27.7 \pm 5.5 \text{ nM}$ for R635A and $33.9 \pm 5.3 \text{ nM}$ for R635E. They are not different from the EC_{50} values found for cAMP ($21.3 \pm 3.3 \text{ nM}$) in WT channels.

Discussion

PKA agonists activate HCN2 channels

Here we performed a comparative study of three cAMP derivatives, *N*⁶-Phe-cAMP, *N*⁶-Bn-cAMP, and *N*⁶-Bnz-cAMP, earlier described as activators of PKA, to investigate their effects on HCN2 channels. In the last decades, these derivatives have been shown to be useful tools when discrimination between activation of PKA and Epac was required (18–22). Interestingly, all three tested derivatives turned out to also be activators for HCN2 channels heterologously expressed in *Xenopus laevis* oocytes by promoting HCN2 channel gating in the presence of a primary hyperpolarizing voltage stimulus.

To study the agonistic effect in more detail, we determined the concentration-activation relationship and quantified EC_{50} as a measure of the apparent affinity and the Hill coefficient of activation. The apparent affinity was considerably affected by the type of *N*⁶ modification: Substituting one of the *N*⁶-bound hydrogens with a phenyl or benzyl group dramatically increased the apparent affinity (seven times and four times higher than cAMP, respectively), whereas a benzoyl ring decreased it (18 times lower than cAMP). However, because EC_{50} is a function of both




Figure 6. Response to *N*⁶-Phe-cAMP after charge neutralization or reversal at position Arg-635 in the CNBD. A, representative current traces for R635A and R635E at zero and saturating cAMP. B, concentration-activation relationships for mHCN2, R635A, and R635E. The Hill equation (Equation 1) was approximated to the relative currents to obtain EC_{50} and the Hill coefficient. C, box plot of EC_{50} values. Filled circles indicate individual recordings. Error bars indicate S.D. EC_{50} values obtained with *N*⁶-Phe-cAMP for R635A and R635E, respectively, are not different from the EC_{50} value obtained for cAMP and mHCN2 (Student's *t* test).

binding affinity and efficacy, this parameter alone does not allow any interpretation of the mechanisms behind the agonist-dependent differences. The Hill coefficients for all agonists were similar to the Hill coefficient for cAMP. Even though this parameter is often used to describe the magnitude of cooperativity in ligand binding to allosteric systems, we hesitate to interpret those numbers in detail because, when derived from electrophysiological measurements, the Hill coefficient is just an empirical description without physical meaning because it depends on both binding and gating (31).

To address the question of why the tested agonists show those clear differences in their apparent affinities, we determined the efficacy, the ability of a ligand to elicit a response upon binding to a receptor (32), compared with unmodified cAMP. Two parameters were quantified: the maximum extent of shifting the steady-state activation to more depolarized voltages, $\Delta V_{1/2}$, and the ability of increasing the current in channels maximally activated by voltage. For both parameters, none of the three agonists differed from cAMP, indicating a similar efficacy of the native ligand and the three derivatives. Following a definition formulated by Colquhoun (31), according to which efficacy is determined by the sum of transduction events that follow the initial binding reaction, in HCN2 channels, those transduction events are similar whether matter they bind *N*⁶-Phe-cAMP, *N*⁶-Bn-cAMP, *N*⁶-Bnz-cAMP, or the native ligand cAMP. Provided that cAMP is a full agonist in HCN2

HCN2 channel activation by N⁶-modified cAMP derivatives




Figure 7. Comparison of relative apparent affinity for PKA and HCN2. A, apparent affinities for cAMP derivatives were related to apparent affinities for unmodified cAMP. Among the tested derivatives, the best discrimination can be realized with N⁶-Bnz-cAMP. Data for PKA were obtained from Refs. 29, 34–36. Filled symbols represent PKAI and empty symbols PKAII. B, sequence alignment comparing the distal parts of the C-helix sequences of mouse and human HCN isoforms with those from A and B sites in regulatory subunits of human PKAI and II. Alignments and structure predictions (α-helix C marked in green) are shown as proposed by Berman *et al.* (39), who used a structure and transformation method (SAT). Prediction of the HCN C-helix follows a suggestion from Lee and MacKinnon (40). The asterisks mark Arg-635 mutated herein. Positively charged residues are shown in red and negatively charged in blue.

channels (33), those data further suggest consideration of all three N⁶-modified derivatives also as full agonists.

In addition to those steady-state parameters, we quantified the activation kinetics of the macroscopic current time course following a hyperpolarizing voltage jump. The kinetics of a macroscopic current reflect the kinetics of the underlying channels and are determined by the rate at which a new equilibrium occurs after a perturbation. We compared the effect of the N⁶-modified derivatives under two conditions: at varying voltages in the presence of a saturating agonist concentration and at varying concentrations at a saturating voltage. For both conditions, the activation time constants for each of the three derivatives were not different from the activation time constants for cAMP. This supports the interpretation of efficacy that the transduction events that follow the initial binding reaction are similar for all tested agonists. Together, those data led us to suggest that the N⁶-modified derivatives tested here are differently potent in HCN2 channels because they differ in their ability to bind to the HCN2 binding sites.

Arginine 635 in the CNBD affects apparent affinities

We performed docking experiments to identify molecular interactions between N⁶ derivatives and binding site residues that might underlie the observed differences in apparent affinities. The binding modes of N⁶-Phe-cAMP and N⁶-Bn-cAMP are stabilized by a cation-π and/or π-π stacking interaction between the additional phenyl moiety and the side chain of Arg-635. The higher apparent affinity of N⁶-Phe-cAMP compared with N⁶-Bn-cAMP is likely explained by the more restricted conformational freedom of the amino-phenyl side chain in the former case, which leads to a reduced loss in configurational entropy upon binding. In contrast, the benzoyl moiety in N⁶-Bnz-cAMP enforces coplanarity of the two aryl systems, which would lead to a clash between the phenyl ring and Arg-635 if the cAMP moiety of N⁶-Bnz-cAMP adopted the usual binding mode in the cAMP binding site. Based on these

results, we hypothesized that the cation-π and/or π-π stacking interaction between the phenyl ring and Arg-635 is the main cause of the differential apparent affinities of N⁶-Phe-cAMP and N⁶-Bn-cAMP versus N⁶-Bnz-cAMP.

To test this hypothesis, we either neutralized or reversed the charge at position 635 by replacing the arginine with either alanine (R635A) or glutamate (R635E). Neutralization resulted in an apparent affinity of N⁶-Phe-cAMP similar to the apparent affinity of cAMP for mHCN2 WT channels. From this result, we suggest that now N⁶-Phe-cAMP interacts with R635A in a similar manner as cAMP with the mHCN2 WT. Reversing the charge by replacing the arginine with a glutamate led to an apparent affinity of N⁶-Phe-cAMP slightly lower than that of cAMP for mHCN2 WT channels. This might be caused by a repulsive force between the aromatic ring of N⁶-Phe-cAMP and the negative side chain of the newly introduced glutamate. Together, these data support the hypothesis resulting from the docking experiments, proposing a stabilizing or destabilizing interaction between N⁶ modifications and Arg-635. A role of Arg-635 for binding and selectivity was discussed earlier by Zhou and Siegelbaum (30). They described this residue as being involved in discriminating between cAMP and cGMP without contributing to efficacy.

Usability of N⁶ modifications in cAMP to discriminate between PKA and HCN channels

What can we learn from the results presented here regarding discrimination between PKA and HCN channel activation? To compare the apparent affinities of the derivatives at HCN2 channels with that at PKA, we plotted relative EC₅₀ values for PKAI and PKAII obtained from the literature (EC₅₀/EC_{50,cAMP}) versus relative EC₅₀ values for HCN2 obtained here (Fig. 7) (29, 34–36).

The very high apparent affinity of N⁶-Phe-cAMP as well as the very low one of N⁶-Bnz-cAMP for HCN2 channels brings the N⁶ position into focus for the search for discriminating ago-

nists. However, in the case of N⁶-Phe-cAMP, the apparent affinity for PKA I and PKAII has also been shown to be relatively high, with a factor of ~2.4 and ~2.8 higher for PKA I and PKAII, respectively, compared with cAMP (29). Thus, the discrimination between HCN and PKA is not very strong.

N⁶-Bn-cAMP was also very potent for HCN2 channels, whereas it was in most cases less potent than cAMP in PKA I (29, 34, 36). The differences are not very high; however, a benzyl ring in the N⁶ position could be at least one of several modifications in the cAMP molecule to yield discrimination between HCN2 and PKA I. A discrimination to PKAII is questionable because the apparent affinity has been shown to be either unchanged (29) or two times better than for cAMP (36).

The derivative with the best discrimination ability found here is N⁶-Bnz-cAMP. It is a potent agonist of PKA I, with a similar apparent affinity as cAMP (29, 35), but a relatively poor agonist of HCN2, with an apparent affinity 18 times worse than cAMP. This is a very important finding because N⁶-Bnz-cAMP is a well-established tool for studying cAMP-mediated signal transduction in a wide range of cellular processes (e.g. 23, 37, 38). Discrimination between PKAII and HCN2 is expected to be less strong because N⁶-Bnz-cAMP is two times less potent to PKAII than cAMP (29, 35).

The C-helix of CNBDs (green bars in Fig. 7) acts as a hydrophobic lid covering the base moiety of the cyclic nucleotide and thereby capping the binding pocket (39). Is the positively charged Arg-635 at the C-terminal end of this C-helix a unique feature of HCN channels and can it be used for further discrimination approaches? The alignment in Fig. 7 shows that, with the exception of mHCN4, Arg-635 is highly conserved in mouse and human HCN channel isoforms, which allows speculation regarding an important role in ligand binding. A comparison with A and B sites of PKA I and PKAII shows that there is no such arginine at the C-terminal ends of the PKA C-helices. However, there is an interesting pattern of charged amino acids right before R635 that reads negative–positive–X–negative–positive and can be found in most HCN channels. This pattern is also present in A sites of PKA RI and, slightly modified, in PKA RII, although not as part of the C-helix sequence but in the consecutive loop directly behind. Such a pattern could not be found in any B sites of PKA presented here. Another pattern in HCN CNBDs is a strong positive spot at the N-terminal part of the C-helix followed by negative residues two positions C-terminal from that. Again this pattern can be found in A sites of PKA RI and additionally in RII but not in B sites. Those differences might be responsible for N⁶-Phe-cAMP, N⁶-Bn-cAMP, and N⁶-Bnz-cAMP preferring A sites over B sites (34, 41).

Because the C-helix is the most variable structure of CNBDs (39), residues in that helix are potential key players in determining protein-specific ligand selectivity. After comparing sequences of HCN CNBDs with A sites and B sites, we speculate that there is a greater similarity between binding to HCN CNBDs and A sites than between HCN CNBDs and B sites. Thus, to identify further cAMP derivatives with a higher degree of discrimination between HCN and PKA than shown here, we propose to focus on the unique characteristics of binding to B sites.

In summary, our analysis shows that possible cross-activation of CN-modulated ion channels should be taken into account when CN-dependent cellular processes are investigated with N⁶-modified derivatives. To overcome this problem, we further suggest that, even with a missing all-or-nothing principle in protein activation by cyclic nucleotides, carefully performed concentration–activation relationships can be used to identify a concentration range in which selective protein activation is possible.

Experimental procedures

X. laevis oocytes as a heterologous expression system

Surgical removal of oocytes was performed under anesthesia (0.3% tricaine, MS-222, Pharmaq Ltd., Fordingbridge, UK) from adult females of the South African claw frog *X. laevis*. The oocytes were treated with collagenase A (3 mg/ml, Roche) for 105 min in Ca²⁺-free Barth's solution containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl₂, and 5 mM Hepes (pH 7.5). After this procedure, oocytes of stages IV and V were manually dissected and injected with cRNA encoding either mHCN2 channels of *Mus musculus* (NM_008226) or the mHCN2 mutants R635A and R635E, respectively. After injection with cRNA, the oocytes were cultured at 18 °C for 2–6 days in Barth's solution containing 84 mM NaCl, 1 mM KCl, 2.4 mM NaHCO₃, 0.82 mM MgSO₄, 0.41 mM CaCl₂, 0.33 mM Ca(NO₃)₂, and 7.5 mM Tris (pH 7.4). The procedures had approval from the authorized animal ethical committee of the Friedrich Schiller University Jena. The methods were carried out in accordance with the approved guidelines. Oocytes harvested in our own laboratory were complemented with ready-to-use oocytes purchased from Ecocyte Bioscience (Dortmund, Germany).

Molecular biology

The mouse HCN2 (accession number NM_008226) channel and the modified subunit variants were subcloned in front of the T7 promoter of pGEM-HCN2. The point mutations R635E and R635A were introduced by overlapping PCR using the following primers: PCR 1 forward, 5'-TCATACTCGCGCGG-CCCCAAGGTTTC-3' (restriction site *MauBI*, outer primer); PCR 1 reverse, 5'-CTTCTTGCTATCTCATCTAGCCGGT-CAATAGC-3' (R635E) or 5'-CTTCTTGCTATGGCATCT-AGCCGGTCAATAGC-3' (R635A); PCR 2 forward, 5'-GCT-ATTGACCGGCTAGATGAGATAGGCAAGAAG-3' (R635E) or 5'-GCTATTGACCGGCTAGATGCCATAGGCAAGAAG-3' (R635A); PCR 2 reverse, 5'-AGCAGGGTTGGTC-TAGAGTCACAAGTTGGAAGAG-3' (restriction site *XbaI*, outer primer). In a third PCR, the PCR products of PCR 1 and 2 were used as a template using the outer primers. The resulting fragment was subcloned into the pGEM-HCN2 subunit. Correctness of the sequences was confirmed by restriction analysis and sequencing (Microsynth SEQLAB). cRNAs were prepared using the mMESSAGE mMACHINE T7 Kit (Ambion).

Electrophysiological experiments

Macroscopic currents were recorded using the patch clamp technique in the inside-out configuration. All measurements were started after a delay of 3.5 min to minimize rundown phe-

nomena. Patch pipettes were pulled from quartz tubing whose outer and inner diameters were 1.0 and 0.7 mm (Vetrocom), respectively, using a laser puller (P-2000, Sutter Instrument). The pipette resistance was 1.2–2.1 megaohm. The bath solution contained 100 mM KCl, 10 mM EGTA, and 10 mM Hepes (pH 7.2), and the pipette solution contained 120 mM KCl, 10 mM Hepes, and 1.0 mM CaCl₂ (pH 7.2). For parts of the experiments, different concentrations of cAMP, N⁶-Phe-cAMP, N⁶-Bn-cAMP, or N⁶-Bnz-cAMP (BIOLOG LSI, Bremen, Germany) were applied with the bath solution. A saturating concentration of 10 μM cAMP was applied to each patch to define the maximum current amplitude. An HEKA EPC 10 USB amplifier (Harvard Apparatus) was used for current recording. Pulsing and data recording were controlled by the Patchmaster software (Harvard Apparatus). The sampling rate was 5 kHz. The holding potential was generally –30 mV.

Quantification and statistical analysis

Concentration–activation relationships were analyzed by approximating the Hill equation to each individual recording using the OriginPro 9.0G software.

$$I/I_{\max} = 1/[1 + (EC_{50}/[\text{agonist}])^H] \quad (\text{Eq. 1})$$

I is the actual current amplitude at a given agonist concentration, $I_{\max}$ the maximal current amplitude at a saturating concentration of 10 μM cAMP, EC_{50} the concentration of half-maximum activation, and H the Hill coefficient. Current amplitudes were generally obtained from tail currents at a –100 mV pulse following an activating –130 mV pulse and corrected for leak currents obtained from a short –100 mV pulse at the beginning of each trace. Values for EC_{50} and H were yielded for each individual recording and averaged. Steady-state activation curves were analyzed by fitting the Boltzmann equation to each individual recording using the OriginPro 9.0G software.

$$I/I_{\max} = 1/[1 + \exp(z\delta F(V - V_{1/2})/RT)] \quad (\text{Eq. 2})$$

$V_{1/2}$ is the voltage of half-maximum activation and $z\delta$ the effective gating charge. F , R , and T are the Faraday constant, the molar gas constant, and the temperature in Kelvin, respectively. I is the actual current amplitude and $I_{\max}$ the maximum current amplitude at the saturating hyperpolarizing voltage of –150 mV specified for each patch.

The time courses of current activation were fitted with a single exponential starting after an initial delay.

$$I(t) = A \times \exp[-t/\tau] \quad (\text{Eq. 3})$$

A is the amplitude, t the time, and τ the time constant for activation.

Experimental data are given as mean ± S.E. Statistical analysis was performed by an unpaired Student's t test. A value of $p < 0.05$ was accepted as statistically significant.

Molecular modeling and docking experiments

Three-dimensional structures of the anionic species of cAMP, N⁶-Phe-cAMP, N⁶-Bn-cAMP, and N⁶-Bnz-cAMP were generated in Maestro (Schrödinger, LLC) and prepared using

the LigPrep workflow (Schrödinger, LLC). One monomer (chain A) of the crystal structure of cAMP-bound mHCN2J (25) was prepared using the Protein Preparation Wizard in Maestro; the program was evoked to cap the termini with acetyl and N -methyl amide moieties and to convert selenomethionine residues back to methionine residues. The potential grid for docking was centered on the cocrystallized cAMP, and the ligand length was set to 16 Å or less. The dimensions of the inner box that restricts the region in which the diameter midpoint of each ligand can be located were set to 10 × 10 × 10 Å. No constraints, rotatable OH- and SH-groups, or excluded volumes were defined. Molecular docking was performed with Glide (Schrödinger, LLC) using the Extra Precision (26) mode with default options.

Author contributions—T. L., M. B., F. Spiegelhalter, and J. K. data curation; T. L., M. B., F. Spiegelhalter, and J. K. formal analysis; T. L., M. B., F. Spiegelhalter, F. Schwede, T. S., H. G., and J. K. methodology; T. L., M. B., F. Spiegelhalter, F. Schwede, T. S., and H. G. writing-review and editing; M. B. and J. K. validation; F. Schwede, H. G., and J. K. conceptualization; F. Schwede and T. S. resources; H. G. and J. K. supervision; H. G. and J. K. funding acquisition; J. K. writing-original draft; J. K. project administration.

Acknowledgments—We thank Sandra Bernhardt, Uta Enke, Andrea Kolchmeier, Claudia Ranke, and Karin Schoknecht for excellent technical assistance. We are grateful for computational support and infrastructure provided by the Zentrum für Informations- und Medientechnologie at the Heinrich Heine University Düsseldorf and the computing time provided by the John von Neumann Institute for Computing (to H. G.) on the supercomputer JUWELS at the Jülich Supercomputing Center (user IDs HKF7 and HDD17).

References

1. Sutherland, E. W., and Rall, T. W. (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. *J. Biol. Chem.* **232**, 1077–1091 [CrossRef Medline](#)
2. Beavo, J. A., and Brunton, L. L. (2002) Cyclic nucleotide research: still expanding after half a century. *Nat. Rev. Mol. Cell Biol.* **3**, 710–718 [CrossRef Medline](#)
3. Schindler, R. F., and Brand, T. (2016) The Popeye domain containing protein family: a novel class of cAMP effectors with important functions in multiple tissues. *Prog. Biophys. Mol. Biol.* **120**, 28–36 [CrossRef Medline](#)
4. Craven, K. B., and Zagotta, W. N. (2006) CNG and HCN channels: two peas, one pod. *Annu. Rev. Physiol.* **68**, 375–401 [CrossRef Medline](#)
5. DiFrancesco, D. (1986) Characterization of single pacemaker channels in cardiac sino-atrial node cells. *Nature* **324**, 470–473 [CrossRef Medline](#)
6. DiFrancesco, D. (1999) Dual allosteric modulation of pacemaker (f) channels by cAMP and voltage in rabbit SA node. *J. Physiol.* **515**, 367–376
7. Robinson, R. B., and Siegelbaum, S. A. (2003) Hyperpolarization-activated cation currents: from molecules to physiological function. *Annu. Rev. Physiol.* **65**, 453–480 [CrossRef Medline](#)
8. Santoro, B., and Tibbs, G. R. (1999) The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels. *Ann. N.Y. Acad. Sci.* **868**, 741–764 [CrossRef Medline](#)
9. Wang, J., Chen, S., Nolan, M. F., and Siegelbaum, S. A. (2002) Activity-dependent regulation of HCN pacemaker channels by cyclic AMP: signaling through dynamic allosteric coupling. *Neuron* **36**, 451–461 [CrossRef Medline](#)
10. Wang, J., Chen, S., and Siegelbaum, S. A. (2001) Regulation of hyperpolarization-activated HCN channel gating and cAMP modulation due to interactions of COOH terminus and core transmembrane regions. *J. Gen. Physiol.* **118**, 237–250 [CrossRef Medline](#)

11. Clapham, D. E. (1998) Not so funny anymore: pacing channels are cloned. *Neuron* **21**, 5–7 [CrossRef Medline](#)
12. Santoro, B., Grant, S. G., Bartsch, D., and Kandel, E. R. (1997) Interactive cloning with the SH3 domain of N-src identifies a new brain specific ion channel protein, with homology to eag and cyclic nucleotide-gated channels. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 14815–14820 [CrossRef Medline](#)
13. Wainger, B. J., DeGennaro, M., Santoro, B., Siegelbaum, S. A., and Tibbs, G. R. (2001) Molecular mechanism of cAMP modulation of HCN pacemaker channels. *Nature* **411**, 805–810 [CrossRef Medline](#)
14. DiFrancesco, D., and Tortora, P. (1991) Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. *Nature* **351**, 145–147 [CrossRef Medline](#)
15. Wicks, N. L., Wong, T., Sun, J., Madden, Z., and Young, E. C. (2011) Cytoplasmic cAMP-sensing domain of hyperpolarization-activated cation (HCN) channels uses two structurally distinct mechanisms to regulate voltage gating. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 609–614 [CrossRef Medline](#)
16. Shabb, J. B., and Corbin, J. D. (1992) Cyclic nucleotide-binding domains in proteins having diverse functions. *J. Biol. Chem.* **267**, 5723–5726 [Medline](#)
17. Rehmann, H., Wittinghofer, A., and Bos, J. L. (2007) Capturing cyclic nucleotides in action: snapshots from crystallographic studies. *Nat. Rev. Mol. Cell Biol.* **8**, 63–73 [CrossRef Medline](#)
18. Chen, L., Wang, P., Andrade, C. F., Zhao, I. Y., Dubé, P. E., Brubaker, P. L., Liu, M., and Jin, T. (2005) PKA independent and cell type specific activation of the expression of caudal homeobox gene Cdx-2 by cyclic AMP. *FEBS J.* **272**, 2746–2759 [CrossRef Medline](#)
19. Hewer, R. C., Sala-Newby, G. B., Wu, Y. J., Newby, A. C., and Bond, M. (2011) PKA and Epac synergistically inhibit smooth muscle cell proliferation. *J. Mol. Cell Cardiol.* **50**, 87–98 [CrossRef Medline](#)
20. Kang, G., Joseph, J. W., Chepurny, O. G., Monaco, M., Wheeler, M. B., Bos, J. L., Schwede, F., Genieser, H. G., and Holz, G. G. (2003) Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca²⁺-induced Ca²⁺ release and exocytosis in pancreatic β -cells. *J. Biol. Chem.* **278**, 8279–8285 [CrossRef Medline](#)
21. Rangarajan, S., Enserink, J. M., Kuiperij, H. B., de Rooij, J., Price, L. S., Schwede, F., and Bos, J. L. (2003) Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β 2-adrenergic receptor. *J. Cell Biol.* **160**, 487–493 [CrossRef Medline](#)
22. Shimomura, H., Imai, A., and Nashida, T. (2004) Evidence for the involvement of cAMP-GEF (Epac) pathway in amylase release from the rat parotid gland. *Arch. Biochem. Biophys.* **431**, 124–128 [CrossRef Medline](#)
23. Christensen, A. E., Selheim, F., de Rooij, J., Dremier, S., Schwede, F., Dao, K. K., Martinez, A., Maenhaut, C., Bos, J. L., Genieser, H. G., and Døskeland, S. O. (2003) cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. *J. Biol. Chem.* **278**, 35394–35402 [CrossRef Medline](#)
24. Ng, L. C. T., Putrenko, I., Baronas, V., Van Petegem, F., and Accili, E. A. (2016) Cyclic purine and pyrimidine nucleotides bind to the HCN2 ion channel and variably promote C-terminal domain interactions and opening. *Structure* **24**, 1629–1642 [CrossRef Medline](#)
25. Zagotta, W. N., Olivier, N. B., Black, K. D., Young, E. C., Olson, R., and Gouaux, E. (2003) Structural basis for modulation and agonist specificity of HCN pacemaker channels. *Nature* **425**, 200–205 [CrossRef Medline](#)
26. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., and Mainz, D. T. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J. Med. Chem.* **49**, 6177–6196 [CrossRef Medline](#)
27. Døskeland, S. O., OGREID, D., Ekanger, R., Sturm, P. A., Miller, J. P., and Suva, R. H. (1983) Mapping of the two intrachain cyclic nucleotide binding sites of adenosine cyclic 3',5'-phosphate dependent protein kinase I. *Biochemistry* **22**, 1094–1101 [CrossRef Medline](#)
28. OGREID, D., Ekanger, R., Suva, R. H., Miller, J. P., and Døskeland, S. O. (1989) Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs. *Eur. J. Biochem.* **181**, 19–31 [CrossRef Medline](#)
29. OGREID, D., Ekanger, R., Suva, R. H., Miller, J. P., Sturm, P., Corbin, J. D., and Døskeland, S. O. (1985) Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination: principles for optimizing the isozyme specificity of analog combinations. *Eur. J. Biochem.* **150**, 219–227 [CrossRef Medline](#)
30. Zhou, L., and Siegelbaum, S. A. (2007) Gating of HCN channels by cyclic nucleotides: residue contacts that underlie ligand binding, selectivity, and efficacy. *Structure* **15**, 655–670 [CrossRef Medline](#)
31. Colquhoun, D. (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. *Br. J. Pharmacol.* **125**, 924–947 [Medline](#)
32. Stephenson, R. P. (1956) A modification of receptor theory. *Br. J. Pharmacol. Chemother.* **11**, 379–393 [CrossRef Medline](#)
33. Flynn, G. E., Black, K. D., Islas, L. D., Sankaran, B., and Zagotta, W. N. (2007) Structure and rearrangements in the carboxy-terminal region of SpH channels. *Structure* **15**, 671–682 [CrossRef Medline](#)
34. Zorn, M., Fladmark, K. E., OGREID, D., Jastorff, B., Døskeland, S. O., and Dostmann, W. R. (1995) Ala335 is essential for high-affinity cAMP-binding of both sites A and B of cAMP-dependent protein kinase type I. *FEBS Lett.* **362**, 291–294 [CrossRef Medline](#)
35. Poppe, H., Rybalkin, S. D., Rehmann, H., Hinds, T. R., Tang, X. B., Christensen, A. E., Schwede, F., Genieser, H. G., Bos, J. L., Døskeland, S. O., Beavo, J. A., and Butt, E. (2008) Cyclic nucleotide analogs as probes of signaling pathways. *Nat. Methods* **5**, 277–278 [CrossRef Medline](#)
36. Chepurny, O. G., Bertinetti, D., Diskar, M., Leech, C. A., Afshari, P., Tsalkova, T., Cheng, X., Schwede, F., Genieser, H. G., Herberg, F. W., and Holz, G. G. (2013) Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. *Mol. Endocrinol.* **27**, 1267–1282 [CrossRef Medline](#)
37. Lo, K. W., Ashe, K. M., Kan, H. M., Lee, D. A., and Laurencin, C. T. (2011) Activation of cyclic amp/protein kinase: a signaling pathway enhances osteoblast cell adhesion on biomaterials for regenerative engineering. *J. Orthop. Res.* **29**, 602–608 [CrossRef Medline](#)
38. Monje, P. V., Athauda, G., and Wood, P. M. (2008) Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. *J. Biol. Chem.* **283**, 34087–34100 [CrossRef Medline](#)
39. Berman, H. M., Ten Eyck, L. F., Goodsell, D. S., Haste, N. M., Kornev, A., and Taylor, S. S. (2005) The cAMP binding domain: an ancient signaling module. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 45–50 [CrossRef Medline](#)
40. Lee, C. H., and MacKinnon, R. (2017) Structures of the human HCN1 hyperpolarization-activated channel. *Cell* **168**, 111–120.e11 [CrossRef Medline](#)
41. Huq, I., Dostmann, W. R., and OGREID, D. (1996) Isoleucine 368 is involved in low-affinity binding of N⁶-modified cAMP analogues to site B of the regulatory subunit of cAMP-dependent protein kinase I. *Biochem. J.* **316**, 337–343 [CrossRef Medline](#)

***N*⁶-modified cAMP derivatives that activate protein kinase A also act as full agonists of murine HCN2 channels**

Tim Leypold, Michele Bonus, Felix Spiegelhalter, Frank Schwede, Tina Schwabe, Holger Gohlke and Jana Kusch

J. Biol. Chem. 2019, 294:17978-17987.

doi: 10.1074/jbc.RA119.010246 originally published online October 15, 2019

Access the most updated version of this article at doi: [10.1074/jbc.RA119.010246](https://doi.org/10.1074/jbc.RA119.010246)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 41 references, 11 of which can be accessed free at <http://www.jbc.org/content/294/47/17978.full.html#ref-list-1>